Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

Mes dernières consult.
Most popular
Analysis summary4-Traders Strategies

Sébastien Gatel

Equity Analyst
share with twitter share with LinkedIn share with facebook
share via e-mail

Big comeback of buyers

Strategy published on 08/16/2016 | 15:01
long trade under condition
Conditional Order Terminated
Entry price : 175$ | Target : 189.6$ | Stop-loss : 170$ | Cancellation Level : 165$ | Potential : 8.34%
Amgen, Inc. shares have recently benefited from a buyers' comeback, which was accompanied by a rise in volumes and volatility. This situation suggests a continuation of the upward dynamic.
Investors should benefit from the breakout of the $ 175 level to target the $ 189.6.
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Historically, the company has been releasing figures that are above expectations.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • The stock is in a well-established, long-term rising trend above the technical support level at 156.08 USD

  • The company's "enterprise value to sales" ratio is among the highest in the world.
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2018 22 585 M
EBIT 2018 11 440 M
Net income 2018 8 234 M
Finance 2018 6 263 M
Yield 2018 2,80%
P/E ratio 2018 15,36
P/E ratio 2019 14,14
EV / Sales 2018 5,53x
EV / Sales 2019 5,35x
Capitalization 131 B
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Duration : Period : Day
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Duration : Period : Week
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders